Humacyte (HUMA) Capital Expenditures (2020 - 2026)
Humacyte (HUMA) posted quarterly Capital Expenditures of $175000.0 for Q1 2026, down 67.89% year-over-year from $545000.0 in Q1 2025, and up 348.72% quarter-over-quarter from $39000.0 in Q4 2025.
Humacyte (HUMA) Capital Expenditures (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Capital Expenditures for 7 consecutive years, with $175000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 67.89% year-over-year to $175000.0; the TTM figure through Mar 2026 stood at $514000.0 (down 70.22% YoY), while the FY2025 annual figure was $884000.0, down 43.77% from the prior year.
- Capital Expenditures grew to $175000.0 in Q1 2026 per HUMA's latest filing, from $39000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.2 million in Q1 2023 and bottomed at $22000.0 in Q1 2022.
- Historically, Capital Expenditures has averaged $350529.4 across 5 years, with a median of $184000.0 in 2024.
- Annual changes were most pronounced in 2023 — Capital Expenditures surged 5136.36% — and 2025, when it sank 94.75%.
- Humacyte's Capital Expenditures stood at $850000.0 in 2022, then sank by 82.35% to $150000.0 in 2023, then sank by 58.0% to $63000.0 in 2024, then tumbled by 38.1% to $39000.0 in 2025, then surged by 348.72% to $175000.0 in 2026.
- Business Quant data shows HUMA's Capital Expenditures at $175000.0 in Q1 2026, $39000.0 in Q4 2025, and $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 104,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104,000.00 |
| Jun 30, 2026 | 104,000.00 |
| Mar 31, 2026 | 175,000.00 |
| Mar 31, 2026 | 175,000.00 |
| Dec 31, 2025 | 39,000.00 |
| Dec 31, 2025 | 39,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 251,000.00 |
| Jun 30, 2025 | 251,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Mar 31, 2024 | 391,000.00 |
| Mar 31, 2024 | 391,000.00 |